Net Profit Margin
since 2005
Calculation
Johnson & Johnson, net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net earnings1 | ÷ | Sales to customers1 | |
|---|---|---|---|---|---|---|---|
| Dec 29, 2024 | 15.84% | = | 100 | × | 14,066) | ÷ | 88,821) |
| Dec 31, 2023 | 41.28% | = | 100 | × | 35,153) | ÷ | 85,159) |
| Dec 31, 2022 | 18.90% | = | 100 | × | 17,941) | ÷ | 94,943) |
| Dec 31, 2021 | 22.26% | = | 100 | × | 20,878) | ÷ | 93,775) |
| Dec 31, 2020 | 17.82% | = | 100 | × | 14,714) | ÷ | 82,584) |
| Dec 29, 2019 | 18.42% | = | 100 | × | 15,119) | ÷ | 82,059) |
| Dec 30, 2018 | 18.75% | = | 100 | × | 15,297) | ÷ | 81,581) |
| Dec 31, 2017 | 1.70% | = | 100 | × | 1,300) | ÷ | 76,450) |
| Dec 31, 2016 | 23.01% | = | 100 | × | 16,540) | ÷ | 71,890) |
| Dec 31, 2015 | 21.99% | = | 100 | × | 15,409) | ÷ | 70,074) |
| Dec 28, 2014 | 21.96% | = | 100 | × | 16,323) | ÷ | 74,331) |
| Dec 29, 2013 | 19.40% | = | 100 | × | 13,831) | ÷ | 71,312) |
| Dec 30, 2012 | 16.14% | = | 100 | × | 10,853) | ÷ | 67,224) |
| Dec 31, 2011 | 14.87% | = | 100 | × | 9,672) | ÷ | 65,030) |
| Dec 31, 2010 | 21.65% | = | 100 | × | 13,334) | ÷ | 61,587) |
| Dec 31, 2009 | 19.82% | = | 100 | × | 12,266) | ÷ | 61,897) |
| Dec 28, 2008 | 20.31% | = | 100 | × | 12,949) | ÷ | 63,747) |
| Dec 30, 2007 | 17.31% | = | 100 | × | 10,576) | ÷ | 61,095) |
| Dec 31, 2006 | 20.73% | = | 100 | × | 11,053) | ÷ | 53,324) |
| Dec 31, 2005 | 20.61% | = | 100 | × | 10,411) | ÷ | 50,514) |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The financial data reveals several notable trends over the analyzed period. Net earnings experienced fluctuations, with an initial gradual increase from 2005 to 2007, followed by a peak in 2008. Thereafter, net earnings showed some volatility, including a significant decline in 2012 and 2017, with a remarkable surge in 2023 before dropping again in 2024. This indicates inconsistencies in profitability over the years.
Sales to customers demonstrated a generally upward trajectory, reflecting steady growth in revenue. From 2005 to 2014, sales increased consistently, peaking around 2017 and 2021. Despite slight dips observed in the years 2015 and 2023, the overall trend signifies expansion in market reach or sales volume, suggesting a solid revenue-generating capability.
The net profit margin mirrored the inconsistencies seen in net earnings. It remained robust in the earlier years, hovering mostly above 17%, with peaks reaching over 23% in certain years such as 2016 and 2021. However, there was a significant anomaly in 2017, where the margin drastically fell to 1.7%, indicating possible extraordinary costs or reduced profitability. Conversely, a sharp increase to over 41% in 2023 stands out as an exceptional case, followed by another notable decline in 2024.
- Net Earnings
- Displayed variability with moderate growth early in the period, sharp declines in some years, and an exceptionally high value in 2023 before falling again.
- Sales to Customers
- Showed steady increase overall, indicating positive revenue growth despite minor year-to-year fluctuations.
- Net Profit Margin
- Experienced general stability with some peaks and troughs, including a dramatic dip in 2017 and an unusually high margin in 2023, reflecting volatility in profitability relative to sales.
Overall, the company’s financial performance reveals growth in sales, while profitability metrics indicate fluctuations possibly linked to operational efficiencies, market conditions, or extraordinary items affecting earnings in certain years. The data suggests that while revenue generation has strengthened over time, profit sustainability has faced challenges requiring further investigation into the causes of margin volatility.
Comparison to Competitors
Johnson & Johnson, net profit margin, long-term trends, comparison to competitors
| Johnson & Johnson | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2024 | 15.84% | 7.59% | 12.77% | -18.53% | 16.33% | 23.51% | 1.68% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 41.28% | 8.95% | 24.96% | 17.83% | 19.94% | 15.36% | 21.03% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 18.90% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 22.26% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 17.82% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 29, 2019 | 18.42% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 30, 2018 | 18.75% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 1.70% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 23.01% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 21.99% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 28, 2014 | 21.96% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 29, 2013 | 19.40% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 30, 2012 | 16.14% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 14.87% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 21.65% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 19.82% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 28, 2008 | 20.31% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 30, 2007 | 17.31% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 20.73% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 20.61% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Johnson & Johnson, net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Johnson & Johnson | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 29, 2024 | 15.84% | 12.30% |
| Dec 31, 2023 | 41.28% | 17.95% |
| Dec 31, 2022 | 18.90% | 22.55% |
| Dec 31, 2021 | 22.26% | 23.38% |
| Dec 31, 2020 | 17.82% | 14.07% |
| Dec 29, 2019 | 18.42% | 23.22% |
| Dec 30, 2018 | 18.75% | 19.82% |
| Dec 31, 2017 | 1.70% | 13.06% |
| Dec 31, 2016 | 23.01% | 20.78% |
| Dec 31, 2015 | 21.99% | 21.17% |
| Dec 28, 2014 | 21.96% | 21.24% |
| Dec 29, 2013 | 19.40% | 21.99% |
| Dec 30, 2012 | 16.14% | 18.53% |
| Dec 31, 2011 | 14.87% | 15.70% |
| Dec 31, 2010 | 21.65% | 15.16% |
| Dec 31, 2009 | 19.82% | 25.73% |
| Dec 28, 2008 | 20.31% | 18.17% |
| Dec 30, 2007 | 17.31% | 15.90% |
| Dec 31, 2006 | 20.73% | 22.24% |
| Dec 31, 2005 | 20.61% | 18.33% |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Johnson & Johnson, net profit margin, long-term trends, comparison to industry (health care)
| Johnson & Johnson | Health Care | |
|---|---|---|
| Dec 29, 2024 | 15.84% | 7.02% |
| Dec 31, 2023 | 41.28% | 9.24% |
| Dec 31, 2022 | 18.90% | 11.62% |
| Dec 31, 2021 | 22.26% | 12.42% |
| Dec 31, 2020 | 17.82% | 8.45% |
| Dec 29, 2019 | 18.42% | 11.58% |
| Dec 30, 2018 | 18.75% | 9.92% |
| Dec 31, 2017 | 1.70% | 8.05% |
| Dec 31, 2016 | 23.01% | 10.68% |
| Dec 31, 2015 | 21.99% | 11.77% |
| Dec 28, 2014 | 21.96% | 12.15% |
| Dec 29, 2013 | 19.40% | 12.81% |
| Dec 30, 2012 | 16.14% | 11.86% |
| Dec 31, 2011 | 14.87% | 10.50% |
| Dec 31, 2010 | 21.65% | 10.48% |
| Dec 31, 2009 | 19.82% | 15.08% |
| Dec 28, 2008 | 20.31% | 11.35% |
| Dec 30, 2007 | 17.31% | 11.02% |
| Dec 31, 2006 | 20.73% | 13.95% |
| Dec 31, 2005 | 20.61% | 13.38% |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).